In a recent article by Genetic Engineering & Biotechnology News, Paul Vulto, PhD, CEO of Mimetas, discusses the growing demand for advanced organ modeling in fields like oncology and metabolic diseases. Mimetas is at the forefront of this innovation, creating sophisticated assays that replicate the complex tumor microenvironment and immune interactions. Their groundbreaking work in liver modeling has produced a life-like liver structure, with significant applications in fibrosis, NASH, and gene therapies, enhancing the accuracy of preclinical testing.
The article also explores the broader shift towards alternative preclinical models, moving beyond traditional animal testing. Companies like Mimetas are leading this charge by developing organ-on-chip systems and microphysiological models that offer more ethical and accurate testing environments. This evolution in preclinical research marks a significant step forward in understanding complex diseases and advancing therapeutic development.
Visit https://www.genengnews.com/topics/cancer/animal-models-and-their-alternatives-share-the-preclinical-habitat/ to read the full article in Genetic Engineering & Biotechnology News.